Primary cultures of pure populations of neuronal or glial cells from the striatum, the cerebral cortex, and the mesencephalon of the mouse embryo were used to look for the presence of opiate receptors coupled to adenylate cyclase. Leu-enkephalin inhibited CAMP production in membranes of embryonic striatal neurons but not in those of other cell types examined. Mu and delta opiate receptors seemed to be coupled negatively to adenylate cyclase in embryonic striatal neurons. It was found that DTLET (a selective delta agonist), as well as DAGO (a selective mu agonist), inhibited CAMP production on these cells. DTLET but not, however, DAGO produced a similar effect on homogenates from the adult rat striatum and on membranes from the neuroblastoma x glioma hybrid cell line NG 108-l 5, two preparations known to possess only delta receptors negatively coupled to adenylate cyclase. The selective kappa agonist U 50.488 was ineffective on all types of membrane preparations used. The inhibitory effects of both DTLET and DAGO on basal adenylate cyclase activity in striatal neurons were reversed by naloxone with a similar efficacy. Two other selective mu agonists, trimu 5 and morphiceptin, inhibited CAMP production in membranes of striatal neurons as well. The nonadditivity of the inhibitory effects of DTLET and DAGO on basal or forskolin-induced activation of adenylate cyclase suggested that mu and delta receptors were colocalized on a similar subpopulation of striatal cells in primary culture. These cells possess dopaminergic receptors of the Dl subtype as well since the amplitude of the inhibitory effects of DTLET and DAGO on CAMP production was increased in the presence of dopamine.
The inhibitory effects of DAGO or DTLET and of somatostatin on adenylate cyclase activity were additive, suggesting that somatostatin receptors coupled negatively to the enzyme may not be localized on striatal neurons possessing mu and delta receptors.
In previous studies, we have used primary cultures of cells from the cerebral cortex, the striatum, and the mesencephalon of mouse embryos in order to characterize and define the cellular localization or colocalization of receptors coupled to adenylate cyclase. Using this approach, adenylate cyclases sensitive to biogenic amines and peptide receptors coupled positively or negatively to the enzyme [vasoactive intestinal peptide (VIP) and somatostatin receptors, respectively] were characterized on pure neuronal populations (Premont et al., 1983; Chneiweiss et al., 1984 Chneiweiss et al., , 1985a Chneiweiss et al., , b, 1986 Chneiweiss et al., , 1987 . In addition, besides P-adrenergic receptors, VIP, and somatostatin receptors coupled to adenylate cyclase could be demonstrated on pure astrocytes (ChneiWeiss et al., 1984 (ChneiWeiss et al., , 1985a (ChneiWeiss et al., , b, 1986 . Differences in the localization of the receptors were seen from one structure to another either on neurons or on glial cells. Finally, information concerning the eventual colocalization of distinct types of receptors on the same cellular population was obtained by determining whether the effects of the corresponding agonists on CAMP production in membrane preparations were additive. For example, all striatal neurons possessing dopamine Dl receptors were also found to possess VIP receptors coupled to adenylate cyclase (Chneiweiss et al., 1985a) . The present investigation was undertaken to determine if opioid receptors coupled to adenylate cyclase were present on either neurons or astrocytes from the cerebral cortex, the striatum, and the mesencephalon of mouse embryos in primary culture. Binding studies on tissues of the adult brain of various species have distinguished 3 main classes of opioids binding sites: mu, delta, and kappa binding sites, which can be recognized by specific ligands or endogenous opioid peptides (Lord et al., 1977; Paterson et al., 1983; Simon, 1987) . Morphine and the synthetic peptide [D-Ala', (Me)Phe4, Gly (OH)5] enkephalin (DAGO) are selective ligands for mu binding sites (Handa et al., 198 1) . (DThrz, Leu5, Thr6) enkephalin (DTLET) is one ofthe most specific ligands for the delta binding sites (Zajac and Roques, 1985) . Kappa binding sites are recognized in particular by the alkaloid U 50.488 (Piercey et al., 1982) . Among pro-enkephalin-derived peptides (Met5)-enkephalin is delta selective, the pro-opiomelanocortin derived beta-endorphin is equipotent at mu and delta sites, while the opioids derived from the prodynorphin molecule are largely kappa-opiate receptor selective (Martin, 1984; Leslie, 1987) . It is now well established that the delta receptor is coupled negatively to adenylate cyclase, as has been shown particularly on the neuroblastoma x glioma hybrid cell line NG 108-15 (Sharma et al., 1975; Law et al., 1981 Law et al., , 1985 . Mu and delta receptors have also been shown in both central and peripheral neurons to increase potassium conductance and therefore to reduce calcium entry indirectly, whereas kappa receptors seem to reduce calcium currents directly (North, 1986) . Using selective ligands we show that, among all cell types examined, the embryonic striatal neurons in primary culture are the only ones Effect of leu-enkephalin (leu-ENK) on adenylate cyclase activity was determined on adult rat striatal membranes and homogenates from neurons or glial cells grown in primary culture originating from 3 brain areas of the mouse embryo. Inhibition of CAMP production due to leu-enkephalin was found only in the adult striatum and in striatal neurons (* p < 0.005 as estimated by Student's t test; n = 4). Each value is the mean f SEM of data obtained in 4 experiments, each individual experiment being performed with triplicate determinations.
possessing delta receptors coupled negatively to adenylate cyclase. Surprisingly, mu agonists were also found to inhibit markedly adenylate cyclase activity on striatal neurons. Additivity experiments suggested that the delta and mu receptors were colocalized on striatal neurons. They also revealed that these opiate receptors could be colocalized also with D 1 dopaminergic (DA) but not somatostatin receptors on a population of striatal neurons.
Materials and Methods
Neuronal primary cultures. Cortical and striatal cells (20 x lo6 each) from 16-d-old Swiss mouse embryos (Iffa Credo) and mesencephalic cells from 14-d-old mouse embryos were dissociated and plated in the absence of fetal calf serum in culture dishes (100 mm diameter, Falcon) previously coated with polyomithine (1.5 pg/ml; MW 40,000; Sigma) as already described (Di Porzio et al., 1980) . The culture medium consisted of a mixture (1: 1) of modified Eagle's medium (MEM) and F-12 nutrient (Gibco), supplemented with glucose (33 mM), glutamine (2 mM), sodium bicarbonate (3 mM), and Hepes (5 mM; Sigma). Fetal calf serum was replaced by a mixture of hormones, proteins, and salts composed of insulin (25 pg/ml; Sigma), transferrin (100 &ml; Sigma), progesterone (20 nM; Merck), putrescine (60 PM; Sigma), and selenium salt NaSeO, (30 nM; Merck). Under these conditions, according to different morphological and histochemical criteria, the number of non-neuronal cells is reduced to less than 5% of the cell population after 7 d in vitro (Prochiantz et al., 1982) .
Glialprimary cultures. The protocol chosen for neurons was also used to start the glial cultures. However, the medium included 10% Nuserum (Collaborative Research) and was changed every 3 d for 4 weeks until glial elements had formed a confluent monolayer, devoid of neuronal cells. As previously described, the absence of surviving neurons was checked by indirect immunofluorescence using an antibody against the 70K neurofilament protein (Chneiweiss et al., 1985b) . More than 95% of the cells could be stained significantly by the immunofluorescence technique using a rabbit antibody directed against glial fibrillary acidic protein (GFAP), indicating that cells were mainly mature astrocytes. A monoclonal antibody from the rat against galactocerebroside and a rabbit antiserum against fibronectin were used to identify the presence of oligodendrocytes and fibroblasts, respectively. No staining could be observed, indicating a lack of these cell types in the cultures. The cultures also were checked to confirm the absence of macrophages using a nonspecific fluorescent immunoglobulin. . Inhibitory effects of leu-enkephalin on basal adenylate cyclase activity in embryonic striatal neurons from the mouse and on adult striatal tissues of the rat. Homogenates of striatal neurons and of astrocytes in primary culture and crude membranes from adult striatal tissue were prepared as described in Materials and Methods. Leu-enkephalin inhibited basal adenylate cyclase activity in striatal neurons (0) and adult striatal tissue (A) but not in striatal astrocytes (0). The inhibitory effects were reversed by naloxone 10m4 M (0). Naloxone alone induced a 12% decrease in adenylate cyclase activity when used at 10m4 M. Since SEMs never exceeded 5% of the mean value, they are not indicated. Basal adenylate cyclase activity (in pmol/lO min/mg protein): striatal neurons, 66 ? 2; striatal astrocytes, 9.1 f 0.8; adult striatum, 747 * 53.
Neuroblastoma-glioma hybrid, NG 108-l 5. The hybrid cells were cultured in Dulbecco's MEM containing HAT (0.1 mM hypoxanthine, 0.4 PM aminopterin, 16 PM thymidine), sodium bicarbonate (3 mM), and 10% fetal calf serum. The cells were grown for 1 week after seeding before use in the experiments.
Homogenate preparation. Following 5-6 d for neuronal cells, 1 week for NG 108-15 cells, and 4 weeks for glial cells, the culture medium was removed and the cells were washed 4 times at room temperature with an isotonic solution (50 mM Tris maleate, 10% sucrose, pH 7.2; wt/vol). A further 1.5 ml of the same buffer was then added, and the cells (20 x 106) were detached using a rubber policeman. The resulting suspension was then homogenized at 4°C by 5 strokes of a Teflon pestle in a Potter Elvehjem glass homogenizer. Homogenates were directly used for adenylate cyclase assay since results were similar to those obtained with crude washed membranes (centrifugation at 100,000 x g, 15 min).
Membranes from the striata of Sprague-Dawley adult male rats and Swiss adult female mouse were also used. For this purpose, striata were dissected at 4°C according to the technique of Glowinski and Iversen (1966) , and striatal homogenates were prepared as just described for cells in culture.
Particulate fractions (100,000 X g, 15 min) were resuspended and washed twice before the adenylate cyclase assay. Adenylate cyclase assay. The reaction was initiated by adding 20 ~1 of the homogenates (5-l 5 pg protein) to 40 pl of the incubation medium [Tris maleate, 50 mM; MgSO,, 0.5 mM; ATP, 0.05 mM; phosphocreatine, 20 mM; creatine kinase, 0.2 mg/ml; BSA fraction V, fatty acid free, 2.5 mg/ml; 3-isobutyl-1-methylxanthine (IBMX) 0.1 mM; GTP, 10 PM; papaverine, 0.1 mM; (&P)-ATP, 1 &i; )H-CAMP, 0.002 &i, pH 7.21. The membranes were incubated at 30°C for 10 min, and the reaction ended by the addition of 100 ~1 of a medium containing sodium dodecyl sulfate, 1% (wt/vol); ATP, 5 mM; CAMP, 2 mM; Tris HCl, 50 mM, pH 7.2. The 3ZP-cAMP formed was isolated according to Salomon et al. (1974) . All determinations were performed in triplicate, whose internal variability was always less than 5% of the obtained values (relative error). Results Leu-enkephalin-induced inhibition of adenylate cyclase activity in mouse embryonic striatal neurons in primary culture Primary cultures of pure neuronal or glial cells from the cerebral cortex, mesencephalon, and striatum were used to look for an effect of leu-enkephalin on adenylate cyclase activity in membranes. As shown in Table 1 , using leu-enkephalin concentrations up to 3 x 10m6 M, striatal neurons were the only cells that responded to the opioid agonist, leu-enkephalin (1O-6 M), producing a 30 + 4% (n = 4) inhibition of the basal adenylate cyclase activity on striatal neuronal membranes. The maximal inhibitory effect of the peptide and its apparent affinity for its receptor on mouse embryonic striatal neurons were slightly higher than those observed on striatal homogenates from the adult rat (Fig. 1) . Naloxone ( 1O-4 M) antagonized the leu-enkephalin inhibitory effect on both preparations (Fig. 1) .
Pharmacological characterization of the opioid receptor negatively coupled to adenylate cyclase on embryonic striatal neurons Binding studies have indicated that DAGO, DTLET, and U 50.488 are selective agonists for the mu, delta, and kappa binding sites, respectively, in the adult brain. The kappa agonist U 50.488 was without effect on adenylate cyclase activity in striatal embryonic neurons. On the other hand, DAGO and DTLET inhibited CAMP production with an almost identical efficacy (Fig. 2) . Hofstee plots of the data revealed an interaction of each agonist with a single class of noninteracting receptors, their apparent affinities (K& being very similar: DTLET, 10.8 * 3.3 x 1O-8 M (n = 5); DAGO, = 3.6 f 0.7 x 1O-8 M (n = 5).
The inhibitory effects of DTLET (3 x lo-' M) and DAGO (3 x 10m7 M) were both antagonized by naloxone up to 3 x 1O-6 M (Fig. 3) . The linear Hofstee plots of the data confirmed that each agonist interacted with a single class of receptors. The calculated apparent affinities of naloxone for the DTLET-and DAGO-sensitive receptors were 8.5 f 5.3 x 1O-9 and 2.3 f 0.9 x 1O-9 M, respectively. For comparison, the effects of DTLET and of DAGO were also examined on the neuroblastoma x glioma hybrid cell line NG 108-l 5, which is known to possess only delta receptors. Experiments were also made on striatal homogenates of the adult rat, which possess both mu and delta binding sites and in which only delta receptors have been reported to be negatively coupled to adenylate cyclase. As illustrated in Figure 4 , DTLET, but not DAGO, markedly inhibited basal adenylate cyclase activity on NG 108-15 membranes, its apparent affinity being similar to that observed on embryonic striatal neurons. DTLET was much more potent than DAGO in inhibiting CAMP production on striatal membranes of the adult rat. Naloxone antagonized the inhibitory effect of DTLET monophasically (data not shown) in both types of preparations, allowing the respective IC,, and K, values to be calculated (Table 2) .
In order to determine whether the inhibitory effect of DAGO on adenylate cyclase activity in embryonic striatal neurons from the mouse was not species dependent, additional experiments were made using striatal membranes of the adult mouse. As observed on striatal membranes of the adult rat, DTLET, but not DAGO, produced a marked inhibition of CAMP production (data not shown).
Finally, 2 other potent mu agonists, trimu 5 and morphiceptin, were used and their effects up to 1O-6 M were tested on both homogenates from striatal neurons in culture and adult rat striatal membranes. A significant inhibition of basal adenylate cyclase activity was observed with both trimu 5 (27 f 3%, n = 3) and morphiceptin (26 f 4%, n = 3) on neurons, whereas only a weak effect, close to that of DAGO, was found on striatal adult tissue (11 f 2% and 8 -t 2% for trimu 5 and morphiceptin, respectively; 12 = 3).
Cellular localization of mu and delta receptors on embryonic striatal neurons in primary culture As previously reported (Premont et al., 1983) , indications about the cellular localization of different types of receptors coupled to adenylate cyclase can be obtained by experiments which determine whether the additive effects of the corresponding agonists are present. Complete additivity of the effects of 2 distinct agonists favors a localization of the corresponding receptors on distinct cellular populations or on distinct cellular domains. represented.
Nonadditivity demonstrates a colocalization of the 2 types of receptors on the same cells. As shown in Figure 5 , the inhibitory effects of DAGO (3 x 1 Om7 M) and DTLET (3 x lo-' M) on basal adenylate cyclase activity were nonadditive. Similar results were obtained in the presence of forskolin (10m5 M), an activator of the adenylate cyclase catalytic subunit. This result suggested that mu and delta receptors were located on the same population of striatal embryonic neurons.
(1 Om5 M) alone markedly stimulated adenylate cyclase activity. In the presence of dopamine (1 O-5 M), the decreases in CAMP production induced by DTLET and DAGO were about twice those observed in the absence of dopamine (Table 3 ). These observations favor the colocalization of opiate receptors with dopaminergic D 1 receptors on a subpopulation of striatal neurons.
Discussion
Complementary experiments were made with somatostatin,
The present study demonstrates that 16-d-old embryonic neuwhich has also been shown to inhibit basal adenylate cyclase rons from the mouse striatum grown for 6 d in primary culture activity in embryonic striatal neurons (Chneiweiss et al., 1985b) .
possess delta opiate receptors negatively coupled to adenylate Interestingly, the inhibitory effects of leu-enkephalin and socyclase. In addition, experiments with DAGO, a selective mu matostatin were completely additive (Fig. 6) . These results inagonist, suggest that mu receptors coupled negatively to the dicate that additive inhibitory effects can be demonstrated and enzyme are also present on these cells. Both types of opiate suggest that opiate and somatostatin receptors are not colocalreceptors (mu and delta) seem to be colocalized on the same ized on the same population of striatal cells or on the same subpopulation of striatal neurons. Interestingly, leu-enkephalin, morphological domain of the cells.
which has been shown in electrophysiologic studies to be as Finally, since dopamine has been shown to modify the charpotent on mu and delta receptors (North, 1986) , did not modify acteristics of the inhibitory response to somatostatin (Chnei-CAMP production either in embryonic neurons from the cere- Weiss et al., 1985b) , similar experiments were made using either bral cortex or mesencephalon, or in astrocytes from the 3 brain DTLET or DAGO, or both. As previously shown, dopamine structures examined. As shown in the adult mouse, rat, and other species, the striatum contains both mu and delta binding sites (Quit-ion et al., 1983; Moskowitz and Goodman, 1984; Eghbali et al., 1987) . Delta binding sites have a diffuse distribution, while the localization of mu binding sites is restricted to the striosomes (Goodman et al., 1980; Herkenham and Pert, 1981 ). An opiate-sensitive adenylate cyclase is present on striatal membranes (Law et al., 1981; Cooper et al., 1982) and as confirmed in the present study, delta receptors are negatively coupled to the enzyme in both adult rats and adult mice. As observed in adult animals, DTLET, a selective agonist of delta receptors (Garbay-Jaureguiberry et al., 1984) inhibited basal CAMP production in membranes of embryonic striatal neurons, and this effect was antagonized by naloxone. Although the patterns of the inhibitory responses were comparable, the apparent affinity of DTLET for the embryonic striatal delta receptors seemed to be slightly higher than that observed in the adult rat. This could be linked to the presence of supersensitive delta opiate receptors on embryonic neurons in primary culture, as has been observed with other types ofreceptors (Premont et al., 1983; Chneiweiss et al., 1984) . However, the apparent affinity of DTLET for inhibiting adenylate cyclase activity in both embryonic neurons and adult striatum was lower than that reported in binding studies. Most likely, this is due to the presence of the high concentration of GTP required in the adenylate cyclase assay for coupling between the agonist receptor complex, the G protein, and the catalytic subunit of adenylate cyclase (Chneiweiss et al., 1987) . Such a sensitivity of opiate agonist binding to GTP has been observed previously on membranes from adult brain tissues and the neuroblastoma x glioma hybrid cell line NG 108-15 (Law et al., 1985; Zajac and Roques, 1985) .
Surprisingly, DAGO, a potent selective agonist of mu receptors, which had a weak effect on striatal membranes of adult animals (rat or mouse) and no effect on the hybrid cell line NG 108-l 5, markedly inhibited CAMP production in membranes from embryonic striatal neurons in primary culture with an efficacy similar to that observed with DTLET. In contrast, the kappa-selective agonist U 50.488 was ineffective. The kinetic characteristics of the DAGO-induced inhibition of adenylate cyclase activity were similar to those observed with DTLET, DAGO even being slightly more potent. Naloxone, an antagonist known to be more effective on mu than delta opiate receptors, reversed the inhibitory effect of DAGO on CAMP production with a higher efficacy than that observed with DTLET. Other selective mu agonists, such as trimu 5 and morphiceptin, inhibited basal adenylate cyclase activity in striatal embryonic neurons with a potency similar to that of DAGO. Our data clearly indicate a coupling of mu receptors with adenylate cyclase in central neurons. It should be recalled that such coupling has been observed in tumor cell line 73 15~ (Frey and Kebabian, 1984) and that mu agonists have been shown to reduce the CAMP efflux from striatal slices of the adult rat (Schoffelmeer et al., 1985 (Schoffelmeer et al., , 1987 . In addition, it has recently been reported that DAGO inhibits CAMP production in homogenates from the neonatal rat forebrain (Milligan et al., 1987) and the adult guinea pig cochlea (Eybalin et al., 1987) .
Electrophysiological studies made in the periphery or CNS indicate that mu and delta opiate receptors can be colocalized on the same cells (Egan and North, 198 1; Zieglgansberger et al., 1982) . Such colocalization of both types of receptors negatively coupled to adenylate cyclase also seems to occur on the same neuronal subpopulation in the striatum of the mouse embryo, since the inhibitory effects of DAGO and DTLET on basal or forskolin stimulated activity of adenylate cyclase were nonadditive. Interestingly, it has been suggested that the different topographic distribution of the mu (striosomes) and delta (diffuse) opiate binding sites in the adult striatum could be modulated by ions and GTP (Bowen et al., 1981) and that these binding sites may be allosterically coupled and may eventually share a common component (Rothman et al., 1985; Bidlack and O'Malley, 1986) . According to this model, differences in the ontogeny or regional distribution in the adult of these 2 types of binding sites could be related to some environmental changes in the membrane composition or cellular activity. It should also be pointed out that the density of mu receptors does not change after birth, whereas that of delta receptors increases 40-fold (Milligan et al., 1987) . This difference in the density of mu and delta receptors could explain the much weaker inhibitory effects of DAGO, trimu 5, and morphiceptin on CAMP production in adult striatal membranes compared with that of DTLET.
A recent investigation in the adult rat striatum has suggested the occurrence of heteroregulation between DA Dl receptors and opiate receptors (Schoffelmeer et al., 1986) . Our results favor the existence of such heteroregulation and indicate that striatal neurons possessing mu and delta receptors also possess DA D 1 receptors. Indeed, the amplitude of the inhibitory effects of DAGO or DTLET was increased in the presence of DA. These results can also be discussed in light of those of Weiss et al. (1985) who reported that the inhibitory effects of opiate and dopaminergic D2 agonists on CAMP production in intact striatal neurons in primary culture were nonadditive. Such a nonadditivity favors colocalization of dopaminergic D2 and opiate receptors on neuronal subpopulations. This allows us to suggest, on the basis of our data, that this subpopulation of sttiatal neurons possesses Dl and D2 dopaminergic receptors, as well as mu and delta opioid receptors coupled to an adenylate cyclase. This conclusion may seem to contradict autoradiographic findings indicating a distinct distribution of Dl (striosomes) and D2 (matrix) receptors in the striatum of adult mammals (Joyce et al., 1986; Besson et al., 1988) . However, as observed for the inhibitory effects of DAGO or DTLET, we have previously shown that the inhibitory effect of somatostatin on adenylate cyclase activity increases in the presence of DA (Chneiweiss et al., 1985b) , indicating colocalization of Dl and somatostatin receptors. Thus, the present results suggest that the Dl receptors are either colocalized with mu and delta opioid receptors or with somatostatin receptors on 2 distinct subpopulations of embryonic striatal neurons. This conclusion is supported by the complete additivity of the inhibitory effects of somatostatin and DAGO or DTLET on basal adenylate cyclase activity.
Besides the striatum, several structures (including the cerebral cortex and mesencephalon) possess delta and mu opiate binding sites in the adult brain (Quirion et al., 1983; Moskowitz and Goodman, 1984) . In fact, the cerebral cortex is one of the structures with the greatest density ofdelta binding sites. Surprisingly, in contrast to results obtained in the striatum, opiate receptors coupled negatively to adenylate cyclase were not found on embryonic neurons from the cerebral cortex and the mesencephalon in primary culture. This is not due to a delayed appearance of functional adenylate cyclase in these cells, since VIP and somatostatin receptors, respectively, stimulate and inhibit the enzyme in these cells (Chneiweiss et al., 1985a, b) . It remains to be determined whether opiate receptors are localized on intrinsic neurons in these structures or whether specific factors are required for the appearance in vitro of functional opiate receptors on neurons from the mesencephalon or cerebral cortex in particular.
During the last few years, an increasing number of functional receptors have been identified on astrocytes (Murphy and Pearce, 1987) and it has been proposed that they could play an important role in the interactions between astrocytes and neurons. This is the case particularly for the VIP receptors coupled to adenylate cyclase that have been characterized on astrocytes from several structures of the mouse brain (Chneiweiss et al., 1985a (Chneiweiss et al., , 1986 . The absence of opiate receptors coupled to adenylate cyclase on astrocytes of all structures examined in the present study suggest that not all neuropeptides are involved in neuron-glia interactions or that opioids may act on glial cells through a second messenger other than CAMP.
